HONG KONG – Japanese pharma major Daiichi Sankyo Co. Ltd., looking to enter the biosimilar game, reported positive results from a co-developed drug that could become the country's first biosimilar etanercept.
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. got the first EU approval for biosimilar etanercept, a win that opens up the European market for a company that is working to become a global top-tier biosimilar maker.
HONG KONG – Japanese pharma major Daiichi Sankyo Co. Ltd., looking to enter the biosimilar game, reported positive results from a co-developed drug that could become the country's first biosimilar etanercept.
HONG KONG – Looking to further its innovative efforts in drug development, pharma major Johnson & Johnson has partnered with Chinese liver disease expert Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), as well as a score of other external companies.
HONG KONG – Looking to further its innovative efforts in drug development, pharma major Johnson & Johnson has partnered with Chinese liver disease expert Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), as well as a score of other external companies.
HONG KONG – New regulations, tighter policies and stronger enforcement in Asia Pacific have increased the risks of fraud in the life science industries and the cost of non-compliance or corruption. Employees in the region are also more conscious of their employers’ ethical record. The result is a need for better and sustainable compliance programs for companies operating across Asia Pacific.
HONG KONG – New regulations, tighter policies and stronger enforcement in Asia Pacific have increased the risks of fraud in the life science industries and the cost of non-compliance or corruption. Employees in the region are also more conscious of their employers' ethical record. The result is a need for better and sustainable compliance programs for companies operating across Asia Pacific.
HONG KONG – New regulations, tighter policies and stronger enforcement in Asia Pacific have increased the risks of fraud in the life science industries and the cost of non-compliance or corruption. Employees in the region are also more conscious of their employers' ethical record. The result is a need for better and sustainable compliance programs for companies operating across Asia Pacific.
HONG KONG – In vitro diagnostics (IVD) specialist Shanghai Kehua Bio-Engineering Co. Ltd. plans to use new R&D and international sales channels to further its antenatal tests and immunodiagnostics businesses, leveraging the end of China's one child policy into future growth.
